# Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).

> **NCT06399341** · — · COMPLETED · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 524 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **DEVICE:** Papilocare vaginal gel

## Key facts

- **NCT ID:** NCT06399341
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399341, "Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06399341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*